Prognostic Value Of Re-TURB Of High Risk Non Invasive Bladder Cancer
Main Category: Urology / NephrologyAlso Included In: Cancer / Oncology
Article Date: 28 Jun 2008 - 3:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
ORLANDO, FL (UroToday.com) - The authors evaluated the usefulness of second TURB and whether pathological outcomes of ReTUR have a prognostic impact on recurrence and progression of primitive T1G3 bladder cancer.
In this study patients with newly diagnosed T1G3 Transitional cell carcinoma of bladder underwent ReTUR 4-6 weeks following the initial TUR. Patients with muscle invasive disease underwent radical cystectomy; those with superficial residual (SRT) and those with no residual tumor (NRT) received a intravesical BCG therapy. In order to evaluate the prognostic significance of ReTUR outcomes, the authors compared recurrence rate, progression rate and recurrence free survival in SRT patients and NRT patients at restaging TUR.
From January 2002 to March 2007 91 patients were enrolled in the study. Restaging TUR revealed residual cancer in 48% of patients. At mean follow up of 27.2 19,8 months, there was statistically significant difference in recurrence rate, progression rate and disease-free survival between no residual tumor patients and patients with non-invasive residual disease (see table)
The authors conclude that ReTUR of T1G3 TCC allows identification of patients with residual and understaged tumors. The outcomes of ReTUR have a prognostic impact on recurrence rate and disease-free survival.
Presented by Roberto C Sanseverino, MD, Antonio Campitelli, MD, Giorgio Napodano, MD, Antonio Barela, MD, Giuseppe Contaldo, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor David P. Wood, MD
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our urology / nephrology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/113147.php>
APA
http://www.medicalnewstoday.com/releases/113147.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



